台灣臨床試驗主持人資料庫|TPIDB

2017-03-01 - 2019-12-31

Phase III

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Condition/Disease

Triple Negative Breast Neoplasms
Test Drug

Pembrolizumab (MK-3475) ；KEYTRUDA®/吉舒達®

Participate Sites
7Sites

Terminated7Sites

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2015-04-01 - 2020-12-31

Phase III

A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine

Condition/Disease

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-12-14 - 2020-10-31

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Condition/Disease

Colorectal Carcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Condition/Disease

Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-02-17 - 2020-12-17

Phase III

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

Condition/Disease

Crohn’s Disease
Test Drug

Filgotinib

Participate Sites
13Sites

Recruiting8Sites

Terminated3Sites

邱正堂

Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

吳登強

Kaohsiung Municipal Gangshan Hospital

未分科

2015-08-15 - 2018-03-28

Phase III

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Condition/Disease

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Test Drug

MEDI4736

Participate Sites
5Sites

Terminated5Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-05-25 - 2028-12-31

Phase III

A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

Condition/Disease

Rheumatoid Arthritis
Test Drug

Filgotinib

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

方耀凡

Linkou Chang Gung Medical Foundation

張棋楨

Taipei Medical University Hospital

2015-08-01 - 2016-07-31

Phase I

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

林昆儒

Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

2015-08-01 - 2018-07-31

Phase II

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2017-08-01 - 2020-07-31

Phase II

Condition/Disease
Test Drug

Participate Sites
1Sites

Suspended1Sites

林昆儒

Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

Search Result

List